179 related articles for article (PubMed ID: 25791770)
1. The emerging role of rituximab in autoimmune blistering diseases.
Ahmed AR; Shetty S
Am J Clin Dermatol; 2015 Jun; 16(3):167-77. PubMed ID: 25791770
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
4. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.
Shetty S; Ahmed AR
Autoimmunity; 2013 Dec; 46(8):487-96. PubMed ID: 24151854
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the treatment of autoimmune subepidermal blistering diseases.
Riquelme-Mc Loughlin C; Estrach T; Morgado-Carrasco D; Fustà-Novell X; Riera-Monroig J; Iranzo P
Dermatol Ther; 2018 Sep; 31(5):e12687. PubMed ID: 30207027
[No Abstract] [Full Text] [Related]
6. Rituximab for autoimmune blistering diseases: recent studies, new insights.
Lunardon L; Payne AS
G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328
[TBL] [Abstract][Full Text] [Related]
7. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
8. Current treatment of autoimmune blistering diseases.
Kasperkiewicz M; Schmidt E
Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
Ahmed AR; Shetty S
Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
[TBL] [Abstract][Full Text] [Related]
10. Practice and Educational Gaps in Blistering Disease.
Ehsani-Chimeh N; Marinkovich MP
Dermatol Clin; 2016 Jul; 34(3):251-6. PubMed ID: 27363880
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
12. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
Li Y; Foshee JB; Sontheimer RD
J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
14. [IgG4-related disease treatment in 2014: Update and literature review].
Grados A; Ebbo M; Jean E; Bernit E; Harlé JR; Schleinitz N
Rev Med Interne; 2015 Jun; 36(6):395-404. PubMed ID: 25595874
[TBL] [Abstract][Full Text] [Related]
15. Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions.
Alaibac M
Front Immunol; 2018; 9():810. PubMed ID: 29720979
[No Abstract] [Full Text] [Related]
16. IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations.
Ahmed AR; Aksoy M
Front Immunol; 2021; 12():727520. PubMed ID: 34646266
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
[TBL] [Abstract][Full Text] [Related]
19. Treatment of autoimmune blistering diseases.
Rico MJ
Cutis; 1993 Dec; 52(6):357-61. PubMed ID: 8293677
[TBL] [Abstract][Full Text] [Related]
20. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication.
Kolesnik M; Becker E; Reinhold D; Ambach A; Heim MU; Gollnick H; Bonnekoh B
J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):771-80. PubMed ID: 23651052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
